November - 2020
Showing Journal 1 of 4
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New Eng J Med, 2020., 383:1827-37
The RNA polymerase inhibitor remdesivir has shown nanomolar in-vitro activity against SARS-CoV-2 in human airway epithelial cells and clinical and virologic efficacy in a primate model of SARS-CoV-2. It has safety data in humans infected with Ebola virus.
This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register
No Comments yet.